Caitlin, what about you? Do you have any experience with this?

Not a whole lot, I'll be honest.

But one other thing that I thought was interesting from these trials was when we looked at those two large RCTs that Danielle was speaking about and the proportion of patients who needed rescue epi during the food challenge, I just thought it was interesting that only, you know, somewhere in the realm of 50 to 60 or 65% on placebo actually needed rescue epinephrine during the food challenge.

Especially because we were talking about in the one RCT, they're getting that 5,000 milligram dose.

Mm-hmm.

So it's just interesting to think that, you know, you may have a child who has a severe peanut allergy and then even without this oral immunotherapy, some of them it looks like will at least have a lower severity of that allergic reaction.

And then, but there has been a, there was a comparison.

Yeah.

And so this was the largest trial and the longest running trial.

This was looking at Pimicrolimus versus corticosteroids.

So we had a head-to-head comparison.

It was funded by the makers of Pimicrolimus.

And it was an open-label RCT of 2,418 infants.

You know, if you look at the absolute difference, they're different because one is more preventative, the other one is sort of treating, I guess.

Caitlin, what about you? Do you have any experience with this?

Not a whole lot, I'll be honest.

But one other thing that I thought was interesting from these trials was when we looked at those two large RCTs that Danielle was speaking about and the proportion of patients who needed rescue epi during the food challenge, I just thought it was interesting that only, you know, somewhere in the realm of 50 to 60 or 65% on placebo actually needed rescue epinephrine during the food challenge.

Especially because we were talking about in the one RCT, they're getting that 5,000 milligram dose.

Mm-hmm.

So it's just interesting to think that, you know, you may have a child who has a severe peanut allergy and then even without this oral immunotherapy, some of them it looks like will at least have a lower severity of that allergic reaction.

Yes.

Yeah.

So the next thing we looked at were topical calcineurin inhibitors, and we found an RCT of 186 infants with mild to moderate eczema.

Um, they were aged three months to 23 months, and this was comparing pimecrolimus 1% twice daily compared to vehicle.

And the outcome they measured was at six weeks.

Um, and they found that the, the percent of infants who had completely controlled or well-controlled eczema at that six-week timeframe was 72% in the pimecrolimus, uh, group, compared to 27% in the group that got vehicle.

And then, uh, but there, there has been a, there was a b- a comparison.

Yeah.